
Cardiac Biomarker Market by Type (Brain Natriuretic Peptide or NT-proBNP, Creatine Kinase, Ischemia Modified Albumin), Location of Testing (Laboratory Testing, Point of Care Testing), Application - Global Forecast 2024-2030
Description
Cardiac Biomarker Market by Type (Brain Natriuretic Peptide or NT-proBNP, Creatine Kinase, Ischemia Modified Albumin), Location of Testing (Laboratory Testing, Point of Care Testing), Application - Global Forecast 2024-2030
The Cardiac Biomarker Market size was estimated at USD 4.62 billion in 2023 and expected to reach USD 5.31 billion in 2024, at a CAGR 14.90% to reach USD 12.24 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Cardiac Biomarker Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cardiac Biomarker Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Cardiac Biomarker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, bioMérieux SA, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., Guangzhou Wondfo Biotech Co., Ltd., Johnson & Johnson Services, Inc., Olympus Corporation, PerkinElmer Inc., Quidel Corporation, Randox Laboratories Ltd., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., and Tosoh Corporation.
Market Segmentation & Coverage
This research report categorizes the Cardiac Biomarker Market to forecast the revenues and analyze trends in each of the following sub-markets:
Type
Brain Natriuretic Peptide or NT-proBNP
Creatine Kinase
Ischemia Modified Albumin
Myoglobin
Troponins
Location of Testing
Laboratory Testing
Point of Care Testing
Application
Acute Coronary Syndrome
Atherosclerosis
Congestive Heart Failure
Myocardial Infarction
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Cardiac Biomarker Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cardiac Biomarker Market?
3. What are the technology trends and regulatory frameworks in the Cardiac Biomarker Market?
4. What is the market share of the leading vendors in the Cardiac Biomarker Market?
5. Which modes and strategic moves are suitable for entering the Cardiac Biomarker Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Cardiac Biomarker Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing incidence of cardiovascular diseases globally
- 5.1.1.2. Increasing awareness and need for early diagnosis of cardiovascular diseases
- 5.1.1.3. Surge in geriatric population and related heart diseases
- 5.1.2. Restraints
- 5.1.2.1. Technical issues pertinent to sample collection and storage
- 5.1.3. Opportunities
- 5.1.3.1. Emerging investment in research and development activities in cardiac biomarkers
- 5.1.3.2. Emerging demand for POC testing with cardiac biomarkers
- 5.1.4. Challenges
- 5.1.4.1. Concerns over regulatory and reimbursement systems
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Cardiac Biomarker Market, by Type
- 6.1. Introduction
- 6.2. Brain Natriuretic Peptide or NT-proBNP
- 6.3. Creatine Kinase
- 6.4. Ischemia Modified Albumin
- 6.5. Myoglobin
- 6.6. Troponins
- 7. Cardiac Biomarker Market, by Location of Testing
- 7.1. Introduction
- 7.2. Laboratory Testing
- 7.3. Point of Care Testing
- 8. Cardiac Biomarker Market, by Application
- 8.1. Introduction
- 8.2. Acute Coronary Syndrome
- 8.3. Atherosclerosis
- 8.4. Congestive Heart Failure
- 8.5. Myocardial Infarction
- 9. Americas Cardiac Biomarker Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Cardiac Biomarker Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Cardiac Biomarker Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Abbott Laboratories
- 13.1.2. Beckman Coulter, Inc.
- 13.1.3. Becton, Dickinson and Company
- 13.1.4. bioMérieux SA
- 13.1.5. DiaSorin S.p.A.
- 13.1.6. F. Hoffmann-La Roche Ltd.
- 13.1.7. Guangzhou Wondfo Biotech Co., Ltd.
- 13.1.8. Johnson & Johnson Services, Inc.
- 13.1.9. Olympus Corporation
- 13.1.10. PerkinElmer Inc.
- 13.1.11. Quidel Corporation
- 13.1.12. Randox Laboratories Ltd.
- 13.1.13. Siemens Healthcare GmbH
- 13.1.14. Thermo Fisher Scientific Inc.
- 13.1.15. Tosoh Corporation
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. CARDIAC BIOMARKER MARKET RESEARCH PROCESS
- FIGURE 2. CARDIAC BIOMARKER MARKET SIZE, 2023 VS 2030
- FIGURE 3. CARDIAC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. CARDIAC BIOMARKER MARKET DYNAMICS
- FIGURE 7. CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 8. CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2023 VS 2030 (%)
- FIGURE 10. CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 12. CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. CARDIAC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. CARDIAC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.